Screener
Kiniksa Pharmaceuticals International, plc KNSA Contract Liabilities, Non-Current
Contract Liabilities, Non-Current at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-087545
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Other current liabilities | 20,052 | 22,134 |
| Total current liabilities | 171,247 | 139,184 |
| Non-current liabilities: | ||
| Non-current deferred revenue | 31,811 | 31,811 |
| Non-current operating lease liabilities | 4,885 | 6,510 |
| Other long-term liabilities | 34,018 | 18,522 |
| Total liabilities | 241,961 | 196,027 |
| Commitments and contingencies (Note 13) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kiniksa Pharmaceuticals International, plc's contract liabilities, non-current?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported contract liabilities, non-current of $31.81M in Q2 2026.
- How has Kiniksa Pharmaceuticals International, plc's contract liabilities, non-current changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's contract liabilities, non-current decreased by 0.0% year-over-year, from $31.81M to $31.81M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's contract liabilities, non-current?
- Over 3 years (2022 to 2025), Kiniksa Pharmaceuticals International, plc's contract liabilities, non-current has grown at a 38.4% compound annual growth rate (CAGR), from $12M to $31.81M.
Ask your AI about Kiniksa Pharmaceuticals International, plc's contract liabilities, non-current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude